Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo‐controlled trials in adults with severe constipation
Neurogastroenterology & Motility · 2023-09 · 35 (9)
DOI: 10.1111/nmo.14632 ↗At a glance
Randomisierte kontrollierte Studie in Neurogastroenterology & Motility, published online on 2023-06-18. Written by Brooks D Cash and 4 co-authors. Institution: Division of Gastroenterology, Hepatology, and Nutrition, University of Texas Health Science Center, Houston, Texas, USA. Major MEDLINE topics: Irritable Bowel Syndrome. Cited 12 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY 4.0). Funded by: Salix Pharmaceuticals, Synergy Pharmaceuticals.
Abstract (original language)
Background
Patients with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS‐C) often experience severe symptoms. The current aim was to evaluate plecanatide in adults with CIC or IBS‐C with severe constipation.
Methods
Data were analyzed post hoc from randomized, placebo‐controlled trials (CIC [ n = 2], IBS‐C [ n = 2]) of plecanatide 3 mg, 6 mg, or placebo administered for 12 weeks. Severe constipation was defined as no complete spontaneous bowel movements (CSBMs) and an average straining score ≥3.0 (CIC; 5‐point scale) or ≥8.0 (IBS‐C; 11‐point scale) during a 2‐week screening. Primary efficacy endpoints were durable overall CSBM responders (CIC: ≥3 CSBMs/week, plus increase from baseline of ≥1 CSBM/week, for ≥9 of 12 weeks, including ≥3 of the last 4 weeks) and overall responders (IBS‐C: ≥30% reduction from baseline in abdominal pain and ≥1 CSBM/week increase for ≥6 of 12 weeks). Key Results Severe constipation was observed in 24.5% (646/2639) and 24.2% (527/2176) of CIC and IBS‐C populations, respectively. The CIC durable overall CSBM response rate (plecanatide 3 mg, 20.9%; plecanatide 6 mg, 20.2%; placebo, 11.3%) and IBS‐C overall response rate (plecanatide 3 mg, 33.0%; plecanatide 6 mg, 31.0%; placebo, 19.0%) were significantly greater with plecanatide versus placebo ( p ≤ 0.01 for all). Median time to first CSBM in CIC and IBS‐C populations were significantly shorter with plecanatide 3 mg versus placebo ( p = 0.01 for both). Conclusions and Inferences Plecanatide was effective in the treatment of severe constipation in adults with CIC or IBS‐C.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Gastroenterology, Hepatology, and Nutrition, University of Texas Health Science Center, Houston, Texas, USA.
- Division of Gastroenterology & Hepatology, Medical College of Georgia, Augusta University, Augusta, Georgia, USA.
- Salix Pharmaceuticals, Bridgewater, New Jersey, USA.
- Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California, Los Angeles, California, USA.
ORCID profiles: Amol Sharma, Lin Chang
Funding
- Salix Pharmaceuticals
- Synergy Pharmaceuticals
Cite
APA
Cash, B. D., Sharma, A., Walker, A., Laitman, A. P., & Chang, L. (2023). Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo‐controlled trials in adults with severe constipation. Neurogastroenterology & Motility, 35(9). https://doi.org/10.1111/nmo.14632
Vancouver
Cash BD, Sharma A, Walker A, Laitman AP, Chang L. Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo‐controlled trials in adults with severe constipation. Neurogastroenterology & Motility. 2023;35(9). doi:10.1111/nmo.14632
BibTeX
@article{Cash2023,
author = {Cash, Brooks D and Sharma, Amol and Walker, Anna and Laitman, Adam P and Chang, Lin},
title = {Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo‐controlled trials in adults with severe constipation},
journal = {Neurogastroenterology & Motility},
year = {2023},
volume = {35},
number = {9},
doi = {10.1111/nmo.14632}
}
EUVIMED